We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$160M
Turnover
14.29%
1-Year Est. Return
8.57%
This Fund
S&P 500
This Quarter
Est. Return
+15.98%
1 Year Est. Return
+8.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$142M
AUM Growth
+$15.4M
(+12%)
Cap. Flow
+$1.25M
Cap. Flow
% of AUM
0.88%
Top 10 Holdings %
Top 10 Hldgs %
49.55%
Holding
52
New
6
Increased
14
Reduced
22
Closed
7
Avg Time Held
1.5
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Solid Biosciences
SLDB
|
+$3.84M |
| 2 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$2.35M |
| 3 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$2.3M |
| 4 |
argenx
ARGX
|
+$2.21M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$2.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$2.33M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$1.98M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$1.84M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$1.76M |
| 5 |
Armstrong World Industries
AWI
|
+$1.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.2% |
| 2 | Financials | 31.36% |
| 3 | Consumer Discretionary | 8.42% |
| 4 | Industrials | 2.47% |
| 5 | Technology | 1.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Madrigal Pharmaceuticals
MDGL
$10.6B
| $2.21M | 1.55% |
17,632
+594
| +3% | +$73.8K |
2018 Q3
2 quarters
|
|
27
Iovance Biotherapeutics
IOVA
$6.67B
| $2.2M | 1.54% |
230,892
-16,750
| -7% | -$163K |
2018 Q2
3 quarters
|
|
28
Rhythm Pharmaceuticals
RYTM
$6.06B
| $2.18M | 1.53% |
79,398
-3,369
| -4% | -$96.8K |
2018 Q4
1 quarter
|
|
29
BioCryst Pharmaceuticals
BCRX
$2.05B
| $2.16M | 1.52% |
265,013
-52,732
| -17% | -$451K |
2018 Q4
1 quarter
|
|
|
ARNA
30
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $2.14M | 1.51% |
+47,779
| New | +$2.19M |
2019 Q1
0 quarters
|
|
31
Heron Therapeutics
HRTX
$71.5M
| $2.11M | 1.49% |
86,477
+2,212
| +3% | +$57.9K |
2018 Q2
3 quarters
|
|
32
Seagate
STX
$157B
| $2.02M | 1.42% |
42,219
-1,444
| -3% | -$64.1K |
2016 Q4
9 quarters
|
|
|
GHDX
33
DELISTED
Genomic Health, Inc.
GHDX
| $2M | 1.41% |
28,619
-1,700
| -6% | -$126K |
2015 Q1
16 quarters
|
|
34
Bread Financial
BFH
$3.89B
| $1.95M | 1.37% |
13,961
+2,046
| +17% | +$279K |
2016 Q4
9 quarters
|
|
35
Morgan Stanley
MS
$286B
| $1.94M | 1.36% |
45,964
+3,221
| +8% | +$136K |
2016 Q4
9 quarters
|
|
36
KKR & Co
KKR
$78.7B
| $1.93M | 1.35% |
82,041
-3,900
| -5% | -$88.8K |
2017 Q4
5 quarters
|
|
37
CBRE Group
CBRE
$39.2B
| $1.91M | 1.34% |
38,566
-4,966
| -11% | -$233K |
2016 Q4
9 quarters
|
|
38
Arcosa
ACA
$7.22B
| $1.87M | 1.32% |
+61,342
| New | +$1.87M |
2019 Q1
0 quarters
|
|
39
Bausch Health
BHC
$2.36B
| $1.87M | 1.32% |
75,828
+2,299
| +3% | +$54.9K |
2018 Q4
1 quarter
|
|
40
Citigroup
C
$207B
| $1.87M | 1.31% |
30,027
+932
| +3% | +$57.9K |
2018 Q2
3 quarters
|
|
41
SLM Corp
SLM
$4.18B
| $1.69M | 1.18% |
170,029
-9,104
| -5% | -$94.2K |
2018 Q2
3 quarters
|
|
42
Trinity Industries
TRN
$2.03B
| $1.65M | 1.16% |
75,769
-5,970
| -7% | -$136K |
2017 Q3
6 quarters
|
|
43
Summit Midstream
SMC
$413M
| $852K | 0.6% |
5,837
| – | – |
2016 Q4
9 quarters
|
|
44
Cocrystal Pharma
COCP
$19.8M
| $417K | 0.29% |
12,743
| – | – |
2018 Q1
4 quarters
|
|
45
State Street SPDR S&P 500 ETF Trust
SPY
$815B
| $266K | 0.19% |
942
+70
| +8% | +$19K |
2017 Q4
5 quarters
|
|
|
46
Alnylam Pharmaceuticals
ALNY
$31.3B
| – | – |
-31,959
| Closed | -$2.33M | – |
|
47
Amazon
AMZN
$2.75T
| – | – |
-3,160
| Closed | -$237K | – |
|
|
48
Armstrong World Industries
AWI
$7.04B
| – | – |
-28,514
| Closed | -$1.66M | – |
|
|
DRNA
49
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-172,524
| Closed | -$1.84M | – |
|
|
XLRN
50
DELISTED
Acceleron Pharma
XLRN
| – | – |
-45,445
| Closed | -$1.98M | – |
|
Similar funds
WH
CPW
SGM
CI
SA
HA
GWA
BRIA
Emory University's Q1 2019 Portfolio in Review
As of Q1 2019, Emory University held 52 positions worth $142M, up 12% from $127M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Emory University's Q1 2019 filing shows 6 new, 14 increased, 22 reduced and 7 closed positions. Its largest new stake was Orchard Therapeutics plc American Depositary Shares: 15,640 shares worth $2.8M. The largest sale was Alnylam Pharmaceuticals, an estimated $2.33M.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 53% a quarter earlier, followed by Financials and Consumer Discretionary.
- Emory University's largest Q1 2019 buy was Orchard Therapeutics plc American Depositary Shares: 15,640 shares worth $2.8M.
- Emory University added most to Solid Biosciences in Q1 2019, an estimated $3.84M increase.
- Emory University's biggest Q1 2019 reduction was Global Blood Therapeutics, Inc., cutting an estimated $829K.
- Emory University fully exited Alnylam Pharmaceuticals in Q1 2019, selling an estimated $2.33M.
- Emory University's ten largest holdings make up 50% of its $142M portfolio in Q1 2019.
- Emory University opened 6 new positions and closed 7 in Q1 2019.
- Emory University's portfolio value rose 12% quarter-over-quarter to $142M.
Based on Emory University's 13F filing for Q1 2019, filed 9 May 2019.